9h
Fintel on MSNWilliam Blair Downgrades Incyte (INCY)Fintel reports that on March 18, 2025, William Blair downgraded their outlook for Incyte (NasdaqGS:INCY) from Outperform to Market Perform. Analyst Price Forecast Suggests 28.39% Upside As of March 4, ...
20h
Fintel on MSNWilliam Blair Upgrades DocuSign (DOCU)Fintel reports that on March 17, 2025, William Blair upgraded their outlook for DocuSign (NasdaqGS:DOCU) from Market Perform ...
Analysts at William Blair lowered their Q1 2025 earnings estimates for Legend Biotech in a research report issued to clients ...
Analysts at William Blair raised their Q1 2025 EPS estimates for Nektar Therapeutics in a research report issued to clients and investors on Thursday, March 13th. William Blair analyst A. Hsieh now ...
Overall, Palantir has had a solid start to 2025. Its growth numbers look impressive, and its AI platform is gaining traction across industries. Yet not everyone is convinced. Some ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results